Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kin Meds vs Rixa Health

Kin Meds
Graded #73

Higher grade

vs+12.400000000000006
Rixa Health
Graded #320

Lower grade

The verdict

Kin Meds takes it — 72.9/100 to 60.5/100.

Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +29
74
45
Dose & formulationKin Meds +42
93
51
Clinical oversightRixa Health +11
74
85
Labs & monitoringRixa Health +10
53
63
FulfillmentRixa Health +6
72
78
Contract termsKin Meds +14
55
41
Kin Meds · left barRixa Health · right bar

The numbers

MetricKin MedsRixa Health
WeighScore72.9/10060.5/100
GradeCC
Scorecard rank#73#320
Semaglutide$149/mo (brand Wegovy)Not disclosed
Tirzepatide$149/mo (brand Zepbound)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesYes
Kin Meds

Graded #73 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described
Rixa Health

Graded #320 · C

Strengths

  • Functional-medicine, root-cause clinical approach
  • Compounded and oral semaglutide plus tirzepatide offered
  • Board-certified DO and FNP providers with years of experience
  • Medication bundled with visits into a single price
  • No charge until after approval

Where it loses points

  • No public monthly pricing; quoted only during consultation
  • Relies on compounded GLP-1, which is not FDA-approved as a finished drug
  • A handful of states still listed as coming soon
  • Branded GLP-1 medications are not the primary offering
  • Requires ongoing monthly follow-up commitment

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard